van Aswegen A, Roodt A, Marais J, Botha J M, Naudé H, Lötter M G, Goedhals L, Doman M J, Otto A C
Department of Biophysics, University of the Orange Free State, Bloemfontein, South Africa.
Nucl Med Commun. 1997 Jun;18(6):582-8. doi: 10.1097/00006231-199706000-00015.
A common complication in patients with breast or prostate cancer is bone metastases causing pain. New radionuclide therapy methods have recently been proposed for palliation, including 186Re-hydroxyethylidene diphosphonate (186Re-HEDP). This paper reports on the local development of 186Re-HEDP and the biodistribution studied in animals for eventual use in patients. Adult dose was computed assuming a 70 kg standard man. The 186Re was labelled to HEDP using standard techniques. The biodistribution in five Chacma baboons (Papio ursinus) was studied. Doses ranging from 39.4 to 44.9 MBq kg(-1) (mean 43.6 +/- 2.8 MBq kg[-1]) were administered, corresponding to an adult human dose of 2960 MBq (80 mCi). Whole-body images of the animals were obtained with a dual-headed scintillation camera on an hourly basis for 6 h post-injection and then daily for 3 days. The bone, soft tissue, kidneys and urinary bladder were considered source organs and data from these organs were used in a compartmental model to obtain the mean residence times of the radionuclide in the different source organs. Radiation dose estimates for 186Re-HEDP were subsequently obtained with the MIRDOSE 3 program. The estimated absorbed radiation doses to some of the organs (expressed in mGy MBq[-l]) were as follows: bone surface 1.69; kidneys 0.09; liver 0.04; ovaries 0.04; red marrow 0.75; total body 0.12; urinary bladder wall 0.43. 186Re-HEDP yielded an effective dose of 0.17 mSv MBq(-1). The radiation dose delivered to the bone marrow in this study did not cause any detrimental effect to the baboons, indicating that locally produced 186Re-HEDP is suitable for clinical use.
乳腺癌或前列腺癌患者的一种常见并发症是骨转移引起疼痛。最近有人提出了新的放射性核素治疗方法用于缓解疼痛，包括186铼-羟基亚乙基二膦酸盐（186Re-HEDP）。本文报道了186Re-HEDP的局部研制情况以及在动物身上进行的生物分布研究，以便最终用于患者。假设标准体重为70千克的成年男性，计算出了成人剂量。采用标准技术将186Re标记到HEDP上。研究了五只南非大狒狒（山魈）的生物分布情况。给予的剂量范围为39.4至44.9 MBq kg(-1)（平均43.6±2.8 MBq kg[-1]），相当于成人剂量2960 MBq（80毫居里）。注射后每小时用双头闪烁相机对动物进行全身成像，持续6小时，然后每天成像，共3天。将骨骼、软组织、肾脏和膀胱视为源器官，并将这些器官的数据用于房室模型，以获得放射性核素在不同源器官中的平均停留时间。随后用MIRDOSE 3程序获得186Re-HEDP的辐射剂量估计值。对一些器官的估计吸收辐射剂量（以mGy MBq[-1]表示）如下：骨表面1.69；肾脏0.09；肝脏0.04；卵巢0.04；红骨髓0.75；全身0.12；膀胱壁0.43。186Re-HEDP产生的有效剂量为0.17 mSv MBq(-1)。本研究中传递到骨髓的辐射剂量未对狒狒造成任何有害影响，表明局部制备的186Re-HEDP适合临床使用。
